Supplementary Materials

Supplementary Material for:

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer

Janos L. Tanyi, Sara Bobisse, Eran Ophir, Sandra Tuyaerts, Annalisa Roberti, Raphael Genolet, Petra Baumgartner, Brian J. Stevenson, Christian Iseli, Denarda Dangaj, Brian Czerniecki, Aikaterini Semilietof, Julien Racle, Alexandra Michel, Ioannis Xenarios, Cheryl Chiang, Dimitri S. Monos, Drew A. Torigian, Harvey L. Nisenbaum, Olivier Michielin, Carl H. June, Bruce L. Levine, Daniel J. Powell Jr., David Gfeller, Rosemarie Mick, Urania Dafni, Vincent Zoete, Alexandre Harari, George Coukos, Lana E. Kandalaft*

*Corresponding author. Email: ana.kandalaft{at}chuv.ch

Published 11 April 2018, Sci. Transl. Med. 10, eaao5931 (2018)
DOI: 10.1126/scitranslmed.aao5931

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Schema of the clinical study.
  • Fig. S2. Analysis of DC vaccine product.
  • Fig. S3. Immune response in patient CTE-0017.
  • Fig. S4. Immune competency of patients.
  • Fig. S5. Clinical response does not depend on prevaccination T cell gene expression.
  • Fig. S6. Validation of CD8+ T cell responses against neoepitopes and wild-type peptides.
  • Fig. S7. Representative example of the gating strategy applied for intracellular cytokine staining analyses.
  • Fig. S8. TCR╬▒ V-J segments recombination landscape of sorted HHAT neoepitope-specific CD8+ T lymphocytes.
  • Table S1. Adverse events detected in cohorts 1 to 3
  • Table S2. Comparative parameters in immune responder and nonresponder patients.
  • Table S3. Gene set enrichment analysis between clinical responders and nonresponders does not find immune-related pathways differentiating both groups of patients before the vaccination.

[Download PDF]